Status:
TERMINATED
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
Lead Sponsor:
BeiGene
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
BGB-A333 is a humanized IgG1-variant monoclonal antibody against programmed cell death 1-ligand 1 (PD-L1), the ligand of an immune check point- receptor, programmed cell death-1 (PD-1). BGB-A317 is a ...
Eligibility Criteria
Inclusion
- Key
- Histologically or cytologically confirmed advanced or metastatic disease (unresectable) that is resistant to standard therapy or for which treatment is not available, not tolerated or refused
- Has Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1
- Has adequate organ function
- Key
Exclusion
- Active brain or leptomeningeal metastasis.
- Active autoimmune diseases or history of autoimmune diseases that may relapse.
- With severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc. (antiviral therapy is permitted for participants with hepatocellular carcinoma)
- Concurrent participation in another therapeutic clinical trial.
- Received prior therapies targeting PD-1 or PD-L1.
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
November 27 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 8 2020
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT03379259
Start Date
November 27 2017
End Date
September 8 2020
Last Update
October 26 2024
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Monash Health
Clayton, Victoria, Australia, 3168
2
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia, 3000
3
Nucleus Network
Melbourne, Victoria, Australia, 3004
4
Linear Clinical Research
Nedlands, Western Australia, Australia, 6009